Regulatory approval

Published by the Health Service Executive. Approved

As monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of the consolidation therapy.

This is written in the approval document.

Reimbursement

ODMS

Citation

Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6808/P707_V2b_Blinatumumab_paed_consolidation.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD19 +, not BCR::ABL1	Acute Lymphoblastic Leukemia	Blinatumomab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2022-05-01	Health Service Executive	Indication approved for reimbursement.